Patent · US Active

ERG/TFF3/HMWCK triple immunostain for detection of prostate cancer

US9678077B2 · kind B2 · utility

0Cited by

0References

17Claims

0Family size

Assignee

Cornell University · IT

Inventors

Mark A. Rubin · New York, US
Juan Miguel Mosquera · New York, US
Kyung Park · Stamford, US
Ya-Lin Chiu · Island Park, US
Francesca Demichelis · New York, US

Key dates

Filing date	May 15, 2013
Grant date	Jun 13, 2017
Priority date	—
Expiry date	Jun 12, 2034

Classification

Technology area (CPC G)Physics
CPC primaryG01N2333/4742
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

This invention relates to a triple immunostaining assay (ERG/TFF3/HMWCK) for sensitive and specific detection of prostate cancer. Positive staining for at least one of ERG or TFF3 combined with negative staining of HMWCK in a sample such as prostate tissue sample is indicative of cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.